| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 09/26/2002 | WO2001076568A3 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 09/26/2002 | WO2001052847A8 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137903 Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes |
| 09/26/2002 | US20020137769 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| 09/26/2002 | US20020137166 ASIP-related proteins |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020136715 Composition comprising a binding agent that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |
| 09/26/2002 | CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/25/2002 | WO2001074354A1 DIURETICS CONTAINING η-TOCOTRIENOL |
| 09/25/2002 | EP1243581A1 Pyridinium compounds useful for the treatment of AGE-related diseases |
| 09/25/2002 | EP1243268A1 Medicinal composition |
| 09/25/2002 | EP1242422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242381A2 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242110A1 A method and composition for treating prostate cancer |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242103A1 Extracts derived from pueraria mirifica, butea superba and/or mucuna collettii and extraction thereof |
| 09/25/2002 | EP1242069A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 09/25/2002 | EP1242068A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 09/25/2002 | EP1242067A2 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 09/25/2002 | EP1070059B1 Chromanone and thiochromanone derivatives |
| 09/25/2002 | EP0972020B1 Insulin-like growth factor agonist molecules |
| 09/25/2002 | EP0925299B1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 09/25/2002 | EP0702551B1 Compositions and methods for reparation and prevention of fibrotic lesions |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |
| 09/25/2002 | CN1371286A Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia |
| 09/25/2002 | CN1371277A Pharmaceutical tramadol salts |
| 09/25/2002 | CN1370574A Antiphlogistic bolus made of honeysuckle, antelope horn and gentian |
| 09/25/2002 | CN1370534A Medicine for treating polycystic kidney disease |
| 09/25/2002 | CN1091376C Process for preparing medicine to treat prostatic diseases |
| 09/24/2002 | US6455674 Polypeptide for use in the diagnosis and treatment of tissue oxygenation defects |
| 09/24/2002 | US6455578 Aromatic derivatives and iron complexes thereof for the use as normalizing agents of the iron level |
| 09/24/2002 | US6455572 Estrogen agonist/antagonist metabolites |
| 09/24/2002 | US6455567 Treating dermatological disorders by administering a 3-(pyrrolidin-2-ylmethyl)-5-(aminosulfonylmethyl)indole |
| 09/24/2002 | US6455562 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/24/2002 | US6455561 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase iv or tumour necrosis factor |
| 09/24/2002 | US6455542 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 09/24/2002 | US6455534 Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| 09/24/2002 | US6455278 Nucleic acid which encodes protein of defined amino acid sequence involved in pain perception; analgesics |
| 09/24/2002 | US6455076 Formulations and methods for reducing skin irritation |
| 09/24/2002 | CA2261426C Benzimidazole cyclooxygenase-2-inhibitors |
| 09/19/2002 | WO2002073213A2 Assay |
| 09/19/2002 | WO2002072832A2 Therapeutic binding molecules |
| 09/19/2002 | WO2002072778A2 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | WO2002072631A2 Mhc molecule constructs and their usesfor diagnosis and therapy |
| 09/19/2002 | WO2002072608A2 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
| 09/19/2002 | WO2002072596A1 Steap-related protein |
| 09/19/2002 | WO2002072585A2 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 09/19/2002 | WO2002072584A2 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 09/19/2002 | WO2002072580A1 Preventives and/or remedies for kidney diseases and kidney failure |
| 09/19/2002 | WO2002072579A1 Triazolopyridines as anti-inflammatory agents |
| 09/19/2002 | WO2002072564A1 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
| 09/19/2002 | WO2002072546A1 Stable crystals of pyrrole compound |
| 09/19/2002 | WO2002072536A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 09/19/2002 | WO2002072127A2 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof |
| 09/19/2002 | WO2002072098A1 Method of treatment |
| 09/19/2002 | WO2002072085A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | WO2002072083A1 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 09/19/2002 | WO2002072010A2 Taxane prodrugs |
| 09/19/2002 | WO2002071874A2 Composition improving age-related physiological deficits and increasing longevity |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002059109A3 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases |
| 09/19/2002 | WO2002055532A3 Variant growth hormone molecules conjugated with macromolecular compounds |
| 09/19/2002 | WO2002050070A3 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2002036140A3 Use of a preparation of cimicifuga racemosa |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002018341A3 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 09/19/2002 | WO2002014311A3 Urea compounds and methods of uses |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002004953A3 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 09/19/2002 | WO2002004487A3 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | WO2001016139A9 Androgen receptor modulator compounds and methods |
| 09/19/2002 | US20020133018 Calcium channel blockers; cardiovascular disorders; side effect reduction |
| 09/19/2002 | US20020132853 Diaryl piperazines and related compounds useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |